CENPW (Centromere Protein W)

Furthermore, predictive modeling and molecular docking revealed that tumors with elevated CENPW levels exhibited enhanced sensitivity to targeted therapies such as OSU-03012 and rapamycin. Collectively, our findings indicate that CENPW acts as a potential oncogenic regulator in KIRC, influencing both immune pathways and therapeutic responsiveness, and may serve as a novel biomarker and treatment target.

CENPW has the potential to function as a molecular marker indicating an unfavorable prognosis in BLCA. Additionally, CENPW exhibits promise as a novel therapeutic target for BLCA.

We identified key genes (CENPW, HORMAD1, APOD, PIP, and ZNF703) associated with poor OS. Thus, these genes might serve as candidate prognostic markers for TNBC.

Notably, inhibition of CEMPW sensitizes breast cancer cells to chemotherapeutic drugs that have been found to induce cell cycle arrest. In summary, these results provide extensive data and experimental evidence that CENPW can serve as a novel predictor of breast cancer and may act as a prospective therapeutic target.

The expression changes of these eight genes in the Gene Expression Omnibus were also highly expressed in LUAD-compared with normal tissues, which confirmed the analysis in the Gene Expression Profiling Interactive Analysis (GEPIA) database. To sum up, we aimed to provide new biomarkers.